ENDO FINANCE LLC and AND ENDO FINCO INC., as Issuers AND EACH OF THE GUARANTORS PARTY HERETO 7.25% SENIOR NOTES DUE 2022 INDENTURE Dated as of May 6, 2014 WELLS FARGO BANK, NATIONAL ASSOCIATION, TrusteeIndenture • May 7th, 2014 • Endo International PLC • Pharmaceutical preparations • New York
INDENTURE dated as of May 6, 2014 among ENDO FINANCE LLC, a Delaware limited liability company and ENDO FINCO INC., a Delaware corporation (each, an “Issuer” and collectively, the “Issuers”), the Guarantors (as defined herein) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG ENDO INTERNATIONAL PLC, BETA ACQUISITION CORP. AND BIOSPECIFICS TECHNOLOGIES CORP. DATED AS OF OCTOBER 19, 2020Agreement and Plan of Merger • October 19th, 2020 • Endo International PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 19, 2020 by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and BioSpecifics Technologies Corp., a Delaware corporation (the “Company”).
ENDO LIMITED, ENDO FINANCE LLC and AND ENDO FINCO INC., as Issuers AND EACH OF THE GUARANTORS PARTY HERETO 6.000% SENIOR NOTES DUE 2023 INDENTURE Dated as of July 9, 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION, TrusteeIndenture • July 9th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
INDENTURE dated as of July 9, 2015 among ENDO LIMITED, a private limited company incorporated under the laws of Ireland, ENDO FINANCE LLC, a Delaware limited liability company and ENDO FINCO INC., a Delaware corporation (each, an “Issuer” and collectively, the “Issuers”), the Guarantors (as defined herein) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 27th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT dated January 27, 2015 (this “Agreement”) is entered into by and among Endo Limited, a private limited company incorporated under the laws of Ireland, Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation (together, the “Issuers”), the guarantors listed in Schedule 1 hereto (the “Initial Guarantors”), and RBC Capital Markets, LLC and Citigroup Global Markets Inc., as representatives (the “Representatives”) of the Initial Purchasers listed in Schedule 1 to the Purchase Agreement (as defined below) (collectively, the “Initial Purchasers”).
ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENTRelease Agreement • April 28th, 2023 • Endo International PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT (this “Agreement”) is hereby entered into as of December 15, 2021, by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”), and James Tursi (“Executive”) (hereinafter collectively referred to as “the parties”).
SUPPLEMENTAL INDENTURESupplemental Indenture • February 28th, 2014 • Endo International PLC • Pharmaceutical preparations • New York
AMENDED AND RESTATED INDENTURE dated as of February 28, 2014 among ENDO FINANCE LLC, a Delaware limited liability company (the “Issuer”), ENDO FINCO INC., a Delaware corporation (the “Co-Obligor”), the Guarantors (as defined herein) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”).
PARTIAL UNWIND AGREEMENT dated as of April 21, 2014 with respect to the Call Option Transaction Confirmation, dated as of April 9, 2008 and the Warrant Confirmation, dated as of April 9, 2008 between Endo Health Solutions Inc. (formerly Endo...Partial Unwind Agreement • August 4th, 2014 • Endo International PLC • Pharmaceutical preparations • New York
THIS PARTIAL UNWIND AGREEMENT (this “Agreement”) with respect to the Call Option Transaction Confirmation (as defined below) and the Warrant Confirmation (as defined below) is made as of April 21, 2014 between Endo Health Solutions Inc. (formerly Endo Pharmaceuticals Holdings Inc.) (the “Company”) and Deutsche Bank AG, London Branch (“Deutsche”).
ENDO INTERNATIONAL PLC PERFORMANCE AWARD AGREEMENT UNDER THE 2015 STOCK INCENTIVE PLANPerformance Award Agreement • May 6th, 2016 • Endo International PLC • Pharmaceutical preparations • Delaware
This Performance Award Agreement (this “Award Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
ENDO INTERNATIONAL PLC PERFORMANCE AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANPerformance Award Agreement • May 7th, 2021 • Endo International PLC • Pharmaceutical preparations • Delaware
This Performance Award Agreement, which shall include the TSR Performance Award Grant Notice, the FCF Performance Award Grant Notice and the Terms and Conditions (collectively, the “Award Agreement”) is made and entered into as of [ ] by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). The Performance Award granted pursuant to this Award Agreement shall consist of [ ] restricted stock units subject to the TSR Performance Award and [ ] restricted stock units subject to the FCF Performance Award (each at target levels of performance and each as defined in the Terms and Conditions). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 7th, 2014 • Endo International PLC • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT dated May 6, 2014 (this “Agreement”) is entered into by and among Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation (together, the “Issuers”), the guarantors listed in Schedule 1 hereto (the “Initial Guarantors”), and RBC Capital Markets, LLC and Deutsche Bank Securities Inc. (each a “Dealer Manager” and, together, the “Dealer Managers”).
ENDO INTERNATIONAL PLC STOCK AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANStock Award Agreement • March 1st, 2017 • Endo International PLC • Pharmaceutical preparations • Delaware
This Stock Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 29th, 2016 • Endo International PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT (this “Agreement”) is hereby entered into as of the 28th day of February, 2016, by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”), and Rajiv De Silva (“Executive”) (hereinafter collectively referred to as “the parties”).
ENDO INTERNATIONAL PLC STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANStock Option Agreement • March 1st, 2017 • Endo International PLC • Pharmaceutical preparations • Delaware
This Stock Option Agreement (this “Option Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the optionee named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
SUPPORT AGREEMENTSupport Agreement • October 19th, 2020 • Endo International PLC • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT, dated as of October 19, 2020 (this “Agreement”), is made and entered into by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and the Marital Trust U/W/O Edwin H. Wegman dated 8-10-06 (the “Stockholder” and, together with Parent and Merger Sub, the “Parties”).
AGREEMENT AND PLAN OF MERGER AMONG AUXILIUM PHARMACEUTICALS, INC. AND ENDO INTERNATIONAL PLC AND ENDO U.S. INC. AND AVALON MERGER SUB INC. October 8, 2014Agreement and Plan of Merger • October 9th, 2014 • Endo International PLC • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made as of October 8, 2014 among Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware (“Auxilium”), Endo International plc, a public limited company incorporated under the laws of Ireland (“Endo”), Endo U.S. Inc., a corporation incorporated under the laws of the State of Delaware (“HoldCo”), and Avalon Merger Sub Inc., a corporation incorporated under the laws of the State of Delaware (“AcquireCo”).
SUPPLEMENTAL INDENTURESupplemental Indenture • February 29th, 2016 • Endo International PLC • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 27, 2015, among the Issuers, the Guarantors (both, as defined in the Indenture referred to below) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
FIFTH SUPPLEMENTAL INDENTURESupplemental Indenture • April 17th, 2014 • Endo International PLC • Pharmaceutical preparations • New York
FIFTH SUPPLEMENTAL INDENTURE (this “Fifth Supplemental Indenture”), dated as of April 17, 2014, among Endo Health Solutions Inc. (formerly known as Endo Pharmaceuticals Holdings Inc.), a Delaware corporation (the “Company”), the Guarantors (as such term is defined in the Indenture) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
ENDO INTERNATIONAL PLC PERFORMANCE AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANPLC Performance Award Agreement • May 7th, 2020 • Endo International PLC • Pharmaceutical preparations • Delaware
This Performance Award Agreement, which shall include the TSR Performance Award Grant Notice, the FCF Performance Award Grant Notice and the Terms and Conditions (collectively, the “Award Agreement”) is made and entered into as of [ ] by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). The Performance Award granted pursuant to this Award Agreement shall consist of [ ] restricted stock units subject to the TSR Performance Award and [ ] restricted stock units subject to the FCF Performance Award (each at target levels of performance and each as defined in the Terms and Conditions). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
SUPPLEMENTAL INDENTURESupplemental Indenture • June 16th, 2020 • Endo International PLC • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of May 28, 2020, among Endo Designated Activity Company (formerly known as Endo Limited), a designated activity company incorporated under the laws of Ireland (the “Company”), Endo Finance LLC (formerly known as Endo Finance Co.), a Delaware limited liability company (“Endo Finance”), Endo Finco Inc., a Delaware corporation (together with the Company and Endo Finance, the “Issuers”), the Guarantors (as defined in the Indenture referred to below) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
SUPPLEMENTAL INDENTURESupplemental Indenture • November 4th, 2019 • Endo International PLC • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 27, 2019, among Endo Finance LLC (formerly known as Endo Finance Co.), a Delaware limited liability company (the “Company”), Endo Finco Inc., a Delaware corporation (together with the Company, the “Issuers”), the Guarantors (as defined in the Indenture) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
24,024,025 ORDINARY SHARES, NOMINAL VALUE US$0.0001 ENDO INTERNATIONAL PLC ORDINARY SHARES UNDERWRITING AGREEMENT JUNE 4, 2015Underwriting Agreement • June 5th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
Endo International plc, a public limited company incorporated under the laws of Ireland (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 24,024,025 ordinary shares of the Company, par value $0.0001 (the “Shares”) (such ordinary shares, the “Firm Securities”) and, at the election of the Underwriters, up to 3,603,603 additional Shares (the “Optional Securities”) (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
LOAN AGREEMENTLoan Agreement • November 17th, 2014 • Endo International PLC • Pharmaceutical preparations • Delaware
This LOAN AGREEMENT, dated as of November 17, 2014 (this “Agreement”), is made by and among Auxilium Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware (“U.S. Borrower”), Auxilium UK LTD, a private company limited by shares registered in England and Wales (“UK Borrower” and, collectively with the U.S. Borrower, the “Borrowers”) and Endo Pharmaceuticals Inc., a corporation incorporated under the laws of the State of Delaware (“Lender”).
AMENDMENT NO. 1 TO CREDIT AGREEMENTCredit Agreement • June 15th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
CREDIT AGREEMENT (this “Agreement”) dated as of February 28, 2014, among ENDO LIMITED, a company duly incorporated under the laws of the Republic of Ireland (Registered Number 534651) (the “Irish Holdco”), Endo Management Limited, a company duly incorporated under the laws of the Republic of Ireland (Registered Number 538432) (the “Irish Sub Holdco”), Endo Luxembourg Holding Company S.à r.l., a société à responsabilité limitée (private limited liability company) incorporated under the laws of Luxembourg, having its registered office at 65, boulevard Grande-Duchesse Charlotte, L-1331 Luxembourg, with a share capital of USD 17,000 and registered with the Luxembourg Register of Commerce and Companies under number B182517 (“Lux Holdco”), Endo Luxembourg Finance Company I S.à r.l., a société à responsabilité limitée (private limited liability company) incorporated under the laws of Luxembourg, having its registered office at 65, boulevard Grande-Duchesse Charlotte, L-1331 Luxembourg, with a
DIRECTOR CONFIDENTIALITY AGREEMENTDirector Confidentiality Agreement • May 5th, 2016 • Endo International PLC • Pharmaceutical preparations • Pennsylvania
THIS DIRECTOR CONFIDENTIALITY AGREEMENT (this “Agreement”) is entered into as of May 5, 2016 and is effective upon the date hereof, by and between Endo International plc, a public limited company incorporated under the laws of Ireland (“Endo”), Todd B. Sisitsky, an individual (“Sisitsky”), and TPG Global, LLC (“TPG” or, either Sisitsky or TPG, a “receiving party”).
AUXILIUM PHARMACEUTICALS, INC., ENDO INTERNATIONAL PLC AND WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Second Supplemental Indenture Dated as of January 29, 2015 to Indenture Dated as of January 30, 2013Endo International PLC • January 30th, 2015 • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE dated as of January 29, 2015 (this “Supplemental Indenture”), among Auxilium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Endo International plc, a public limited company incorporated under the laws of Ireland (“Endo”), and Wells Fargo Bank, National Association, a national banking association, as trustee (the “Trustee”), supplementing the Indenture, dated as of January 30, 2013 (the “Base Indenture”), as supplemented by the First Supplemental Indenture, dated as of January 30, 2013 (the “First Supplemental Indenture,” and together with the Base Indenture, the “Indenture”), between the Company and the Trustee.
ENDO INTERNATIONAL PLC STOCK AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANPLC Stock Award Agreement • November 8th, 2018 • Endo International PLC • Pharmaceutical preparations • Delaware
This Stock Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
PURCHASE AGREEMENTPurchase Agreement • May 11th, 2015 • Endo International PLC • Pharmaceutical preparations • Delaware
This Purchase Agreement (this “Agreement”), dated as of March 2, 2015, is entered into by and among American Medical Systems Holdings Inc., a Delaware corporation (“AMS Seller”), Endo Health Solutions Inc., a Delaware corporation (the “Foreign Sub Seller,” or, together with AMS Seller, the “Sellers”), and Boston Scientific Corporation, a Delaware corporation (“Purchaser”).
March 28, 2019 Par Pharmaceutical, Inc., (as Issuer) and Each of the Guarantors Party hereto and Wells Fargo Bank, National Association (as Trustee) INDENTURE 7.500% Senior Secured Notes due 2027Supplemental Indenture • March 28th, 2019 • Endo International PLC • Pharmaceutical preparations • New York
INDENTURE dated as of March 28, 2019 among PAR PHARMACEUTICAL, INC., a New York corporation (the “Issuer”), the Guarantors (as defined herein) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association organized under the laws of the United States, as trustee (the “Trustee”).
ENDO INTERNATIONAL PLC LONG-TERM CASH INCENTIVE AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANAward Agreement • August 8th, 2018 • Endo International PLC • Pharmaceutical preparations • Delaware
This Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
ENDO INTERNATIONAL PLC LONG-TERM CASH AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANAward Agreement • May 7th, 2021 • Endo International PLC • Pharmaceutical preparations • Delaware
This Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
ENDO INTERNATIONAL PLC STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLANPLC Stock Option Agreement • November 8th, 2018 • Endo International PLC • Pharmaceutical preparations • Delaware
This Stock Option Agreement (this “Option Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the optionee named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s Amended and Restated 2015 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
COLLATERAL TRUST AGREEMENT dated as of April 27, 2017 among ENDO INTERNATIONAL PLC, ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L., ENDO LLC, ENDO DESIGNATED ACTIVITY COMPANY, ENDO FINANCE LLC, ENDO FINCO INC., the other Grantors from time to time party...Collateral Trust Agreement • June 16th, 2020 • Endo International PLC • Pharmaceutical preparations • New York
COLLATERAL TRUST AGREEMENT, (as amended, restated, supplemented, amended and restated or otherwise modified from time to time, this “Agreement”) dated as of April 27, 2017 among Endo International PLC, a company incorporated under the laws of Ireland (Registered Number 534814) (the “Parent”), Endo Luxembourg Finance Company I S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg,1 (the “Lux Borrower”), Endo Luxembourg Holding Company S.à r.L., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg,2 Endo Luxembourg Finance Company II S.à r.l.,3 a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg, Endo US Holdings Luxembourg I S.à r.l., a private limited liability company (société à responsabilité limitée), incorporated under the laws of Luxembourg,4 Endo US Holdings Luxembourg II S.à r.l., a private l
June 16, 2020 Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (as Issuers) and Each of the Guarantors Party hereto and Wells Fargo Bank, National Association (as Trustee) INDENTURE 9.500% Senior Secured Second Lien Notes due 2027Supplemental Indenture • June 16th, 2020 • Endo International PLC • Pharmaceutical preparations • New York
INDENTURE dated as of June 16, 2020 among ENDO DESIGNATED ACTIVITY COMPANY, a designated activity company incorporated under the laws of Ireland (“Endo DAC”), ENDO FINANCE LLC, a Delaware limited liability company (“Endo Finance”), ENDO FINCO INC., a Delaware corporation (“Endo Finco” and, together with Endo DAC and Endo Finance, the “Issuers”), the Guarantors (as defined herein) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association organized under the laws of the United States, as trustee (the “Trustee”).
SUPPLEMENTAL INDENTURESupplemental Indenture • November 9th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
WHEREAS, the Company, Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation, have heretofore executed and delivered to the Trustee an indenture, dated as of January 27, 2015, as supplemented by a supplemental indenture, dated as of February 3, 2015, a supplemental indenture, dated as of March 20, 2015, a supplemental indenture, dated as of March 27, 2015, a supplemental indenture, dated as of June 24, 2015, and a supplemental indenture, dated as of July 9, 2015, in each case, by and among the parties thereto (the “Indenture”), providing for the issuance of 6.00% Senior Notes due 2025 (the “Notes”);
SUPPLEMENTAL INDENTURESupplemental Indenture • November 9th, 2015 • Endo International PLC • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of September 30, 2015, among Par Pharmaceutical Companies, Inc., a Delaware corporation, Par Pharmaceutical, Inc., a Delaware corporation, Anchen Incorporated, a Delaware corporation, Par, Inc., a Delaware corporation, Anchen Pharmaceuticals, Inc., a California corporation, JHP Group Holdings, Inc., a Delaware corporation, JHP Acquisition, LLC, a Delaware limited liability company, Par Sterile Products, LLC, a Delaware limited liability company, Kali Laboratories, Inc., a New Jersey corporation, Innoteq, Inc., a Connecticut corporation, Par Laboratories Europe, Ltd., a company organized under the laws of the United Kingdom and Endo Finance IV Limited, a private limited company incorporated under the laws of Ireland (each, a “Guaranteeing Subsidiary” and collectively, the “Guaranteeing Subsidiaries”), subsidiaries of Endo Designated Activity Company, a private limited company incorporated under the laws of Ireland (the “Co
